Thrombosis and cancer

Bleeding complications and platelet dysfunction in patients with lymphoproliferative disease receiving Bruton tyrosine kinase inhibitors

Ibrutinib (IBR) is an irreversible inhibitor of Bruton tyrosine kinase (Btk) that is approved for the treatment of...

Cancer is associated with an increased risk of venous but also arterial thrombosis1. Moreover, contemporary anticancer...

Max is a 61-year-old male who works as a consultant cardiologist at your same institution and who has recently been...

New perspectives for the treatment of cancer-associated thrombosis Patients with cancer-associated thrombosis (CAT)...

The past decade has seen a large number of studies focusing on identifying cancer patients at high risk for venous...

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, can be the first sign of an...

Mari Tinholt1,2, Nina Iversen1 and Per Morten Sandset2,3,* 1Department of Medical Genetics, Oslo University Hospital,...

Cancer-associated venous thromboembolism (VTE) causes significant morbidity and mortality in patients and constitutes...

The landmark CLOT Study changed practice by demonstrating that dalteparin monotherapy was more effective than LMWH...

Major bleeding can be life or limb threatening and incurs substantial health care costs, whereas clinically relevant...